MARKET

REGN

REGN

Regeneron Pharmaceuticals
NASDAQ
837.43
+16.53
+2.01%
Opening 09:57 12/06 EST
OPEN
825.55
PREV CLOSE
820.90
HIGH
837.43
LOW
824.82
VOLUME
40.17K
TURNOVER
0
52 WEEK HIGH
853.97
52 WEEK LOW
668.00
MARKET CAP
91.24B
P/E (TTM)
23.89
1D
5D
1M
3M
1Y
5Y
Analysts’ Top Healthcare Picks: Sanofi (SNYNF), Regeneron (REGN)
TipRanks · 1d ago
EyePoint Pharmaceuticals Soaring On Wet AMD Study Results: Durasert Looks Real Deal
Eyepoint pharmaceuticals, inc. Is a potential treatment for wet age-related macular degeneration. Eyp-1901 showed positive results in a phase 2 study of the drug in a small group of patients. The drug met all primary and secondary endpoints in the study. Eyepoint's stock price has soared from $6 to $18 in the last month.
Seeking Alpha · 1d ago
EyePoint (EYPT) Surges 178% on Upbeat Phase II Eye Disease Data
NASDAQ · 1d ago
Replimune Shares Plunge As Skin Cancer Therapy Fails To Meet Primary Clinical-Trial Goals -- MarketWatch
Replimune group inc. Shares drop more than 40% premarket. Biotech company says cancer therapy failed to meet primary goals in skin cancer clinical trial. The company says it will halt development of two other cancer therapies. Replimune shares have dropped 55% in the year to date.
MarketWatch · 2d ago
Analysts Conflicted on These Healthcare Names: Regeneron (REGN), AbbVie (ABBV) and Taysha Gene Therapies (TSHA)
TipRanks · 2d ago
You Don't Have to Pick a Winner in Gene-Editing. Do This Instead.
Gene editing could unlock billions of dollars in latent value for investors. Crispr therapeutics and intellia are among the early leaders in the gene editing field. The field's uncertain future makes gene editing stocks worth owning as a hedge against the field's long-term prospects.
The Motley Fool · 3d ago
EyePoint Pharma surges as wet AMD therapy succeeds in mid-stage trial
Eyepoint pharmaceuticals' anti-vegf therapy eyp-1901 succeeds in phase 2 wet age-related macular degeneration trial. Shares of the company climbed261% in pre-market monday. Eyepoint says the drug is superior to regeneron's eylea therapy in wet amd.
Seeking Alpha · 3d ago
Weekly Report: what happened at REGN last week (1127-1201)?
Weekly Report · 3d ago
More
About REGN
Regeneron Pharmaceuticals, Inc. is an integrated biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. The Company's commercialized medicines and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic conditions, infectious diseases and rare diseases. It helps in accelerating and improving the traditional drug development process through its VelociSuite technologies, such as VelocImmune, which uses genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies, and through research initiatives, such as Regeneron Genetics Center. It operates gene therapy programs targeting different forms of congenital, monogenic hearing loss. Its advanced clinical-stage candidate is DB-OTO, which is an investigational cell-selective, adeno-associated virus (AAV) gene therapy.

Webull offers Regeneron Pharmaceuticals Inc stock information, including NASDAQ: REGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, REGN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading REGN stock methods without spending real money on the virtual paper trading platform.